FindTrial
Sign In

The Role and Mechanism of Omega-3 Unsaturated Fatty Acids in Left Heart Disease-Associated Pulmonary Hypertension

The Role and Mechanism of Omega-3 Unsaturated Fatty Acids in Left Heart Disease-Associated Pulmonary Hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091225
Enrollment
Unknown
Registered
2024-10-23
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left heart disease-associated pulmonary hypertension (PH-LHD)

Interventions

Low-level group:None
Medium-level group:None
High-level group:None

Sponsors

Shijiazhuang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patients with a confirmed diagnosis of heart failure with reduced ejection fraction, mildly reduced ejection fraction, or preserved ejection fraction, as well as patients with left-sided valvular heart disease; echocardiography indicating signs of pulmonary hypertension; complete medical records; and patients who voluntarily participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Patients with a confirmed diagnosis of idiopathic pulmonary arterial hypertension, pulmonary obstructive diseases, hematological disorders, respiratory diseases, connective tissue diseases, congenital heart disease, or malignant tumors; patients with varying degrees of liver or kidney dysfunction; and patients with psychiatric disorders, drug dependence, or cognitive impairment.

Design outcomes

Primary

MeasureTime frame
Omega-3 Unsaturated Fatty Acids;—

Countries

China

Contacts

Public ContactXiaoyue Qin

Shijiazhuang People's Hospital

mdl0871@163.com+86 186 3348 7667

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026